This phase @ , randomized , double-blind , placebo-controlled , comparative study aimed to confirm the superiority of @ week luseogliflozin @ mg monotherapy over placebo in reducing hemoglobin A@c ( HbA@c ) levels in Japanese patients with type @ diabetes mellitus ( T@DM ) .